{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:34:20Z","timestamp":1779298460693,"version":"3.51.4"},"reference-count":105,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Although the literature on patient-reported outcomes (PROMs) continues to expand, challenges persist in selecting reliable and valid instruments for assessing peripheral neuropathy (PN) in patients with cancer. This systematic review aimed to identify all validated self-report PN scales and critically appraise their measurement properties. This review was conducted using the COSMIN methodology for PROMs and the PRISMA statement. Five databases were searched from inception to August 2024, identifying 46 eligible studies and 16 PROMs. Evidence quality ranged from \u201cvery low\u201d to \u201cmoderate\u201d, with notable inconsistencies in the content and structural validity phases of most instruments. Instruments such as the Chemotherapy-induced peripheral neuropathy assessment tool and the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2013Neurotoxicity demonstrated moderate quality and potential utility in clinical practice, while others, including the Location-based assessment of sensory symptoms in cancer and the Measure of Ovarian Symptoms and Treatment, had insufficient evidence to support their use. Importantly, all PROMs focused on chemotherapy-induced peripheral neuropathy, highlighting a significant gap in instruments addressing other PN causes, such as radiotherapy or tumor-related nerve damage. Further research should prioritize developing and validating instruments for distinct cancer populations, ensuring robust psychometric properties and clinical applicability.<\/jats:p>","DOI":"10.3390\/curroncol31120577","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T09:55:20Z","timestamp":1733478920000},"page":"7828-7851","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-2410","authenticated-orcid":false,"given":"Silvia","family":"Belloni","sequence":"first","affiliation":[{"name":"Department of Public Health, Experimental and Forensic Medicine, Section of Hygiene, University of Pavia, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-6940","authenticated-orcid":false,"given":"Arianna","family":"Magon","sequence":"additional","affiliation":[{"name":"Health Professions Research and Development Unit, IRCCS Policlinico San Donato, San Donato Milanese, 20097 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4829-7640","authenticated-orcid":false,"given":"Chiara","family":"Giacon","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Savioni","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-8203","authenticated-orcid":false,"given":"Gianluca","family":"Conte","sequence":"additional","affiliation":[{"name":"Health Professions Research and Development Unit, IRCCS Policlinico San Donato, San Donato Milanese, 20097 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-6209","authenticated-orcid":false,"given":"Rosario","family":"Caruso","sequence":"additional","affiliation":[{"name":"Health Professions Research and Development Unit, IRCCS Policlinico San Donato, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Biomedical Sciences for Health, University of Milan, 20126 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Arrigoni","sequence":"additional","affiliation":[{"name":"Department of Public Health, Experimental and Forensic Medicine, Section of Hygiene, University of Pavia, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00520-024-08466-7","article-title":"Summary of Evidence on Comprehensive Healthcare for Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients","volume":"32","author":"Dan","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Klafke, N., Bossert, J., Kr\u00f6ger, B., Neuberger, P., Heyder, U., Layer, M., Winkler, M., Idler, C., Kaschdailewitsch, E., and Heine, R. (2023). Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) with Non-Pharmacological Interventions: Clinical Recommendations from a Systematic Scoping Review and an Expert Consensus Process. Med. Sci., 11.","DOI":"10.3390\/medsci11010015"},{"key":"ref_3","unstructured":"(2024, June 27). The Foundation for Peripheral Neuropathy Our Mission. Available online: https:\/\/www.foundationforpn.org\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/jns.12337","article-title":"Toxic Neuropathy Consortium of the Peripheral Nerve Society Chemotherapy-Induced Peripheral Neurotoxicity: A Multifaceted, Still Unsolved Issue","volume":"24","author":"Cavaletti","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, Prevalence, and Predictors of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_7","unstructured":"(2024, June 26). National Institute of Neurological Disorders and Stroke Peripheral Neuropathy, Available online: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/peripheral-neuropathy."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-Induced Peripheral Neuropathy: Part 1\u2014Current State of Knowledge and Perspectives for Pharmacotherapy","volume":"72","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_9","unstructured":"Hammi, C., and Yeung, B. (2022). Neuropathy. StatPearls, StatPearls Publishing."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15347354231185110","DOI":"10.1177\/15347354231185110","article-title":"Neurological Outcomes of Chemotherapy-Induced Peripheral Neuropathy in Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"22","author":"Suzuki","year":"2023","journal-title":"Integr. Cancer Ther."},{"key":"ref_11","unstructured":"(2024, June 26). National Cancer Institute Nerve Problems (Peripheral Neuropathy) and Cancer Treatment, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nerve-problems."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-020-00903-0","article-title":"The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy","volume":"22","author":"Tofthagen","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Alkandari, M., and Hollywood, A. (2023). People\u2019s Experiences Living with Peripheral Neuropathy: A Qualitative Study. Front. Pain Res., 4.","DOI":"10.3389\/fpain.2023.1162405"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-Induced Peripheral Neuropathy and Its Association with Quality of Life: A Systematic Review","volume":"22","author":"Mols","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-011-1336-0","article-title":"Assessing the Impact of Chemotherapy-Induced Peripheral Neurotoxicity on the Quality of Life of Cancer Patients: The Introduction of a New Measure","volume":"20","author":"Driessen","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"151499","DOI":"10.1016\/j.soncn.2023.151499","article-title":"Real-Life Experiences of Chemotherapy-Induced Peripheral Neuropathy in Patients with Cancer: A Qualitative Meta-Synthesis Study","volume":"39","author":"Kim","year":"2023","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NAJ.0000742060.56042.e7","article-title":"CE: Chemotherapy-Induced Peripheral Neuropathy","volume":"121","author":"Knoerl","year":"2021","journal-title":"AJN Am. J. Nurs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5430\/cns.v8n3p45","article-title":"The Effect of Peripheral Neuropathy on Daily Life Activities in Patients Receiving Chemotherapy","volume":"8","author":"Bicakci","year":"2020","journal-title":"Clin. Nurs. Stud."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5505\/aot.2020.48992","article-title":"The Evaluation of Peripheral Neuropathy, Daily Life Activities and Quality of Life in Cancer Patients","volume":"53","year":"2020","journal-title":"Acta Haematol. Oncol. Turc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","article-title":"Chemotherapy-Induced Peripheral Neuropathy and Its Impact on Health-Related Quality of Life among Ovarian Cancer Survivors: Results from the Population-Based PROFILES Registry","volume":"135","author":"Ezendam","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/0284186X.2021.1917776","article-title":"Chemotherapy-Induced Peripheral Neuropathy after Modern Treatment of Hodgkin\u2019s Lymphoma; Symptom Burden and Quality of Life","volume":"60","author":"Eikeland","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.12998\/wjcc.v10.i15.4843","article-title":"Psychosocial Adaptation and Influencing Factors among Patients with Chemotherapy-Induced Peripheral Neuropathy","volume":"10","author":"Zhou","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5152\/FNJN.2024.22333","article-title":"The Effect of Peripheral Neuropathy on Disability and Anxiety","volume":"32","author":"Uysal","year":"2024","journal-title":"Florence Nightingale J. Nurs."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000097","DOI":"10.1136\/esmoopen-2016-000097","article-title":"ESMO\/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016","volume":"1","author":"Dittrich","year":"2016","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/JPR.S409580","article-title":"Nursing Dilemmas in Chemotherapy-Induced Peripheral Neuropathy: A Qualitative Study of a Tertiary Hospital in China","volume":"16","author":"Fan","year":"2023","journal-title":"J. Pain. Res."},{"key":"ref_26","unstructured":"(2024, June 27). Oncology Nursing Society Peripheral Neuropathy. Available online: https:\/\/www.ons.org\/pep\/peripheral-neuropathy."},{"key":"ref_27","first-page":"480","article-title":"Definire Le Priorit\u00e0 Tra Le Attivit\u00e0 Scientifiche Dell\u2019Associazione Italiana Degli Infermieri Di Area Oncologica (AIIAO): Validazione Di Un Questionario e Studio Pilota|A Bottom-up Approach to Prioritize the Scientific Activities of Italian Association of Cancer Nurses (AIIAO): Questionnaire Validation and Pilot Study","volume":"110","author":"Caruso","year":"2019","journal-title":"Recent. Progress. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdv181","article-title":"Patient-Reported Outcomes in Routine Cancer Clinical Practice: A Scoping Review of Use, Impact on Health Outcomes, and Implementation Factors","volume":"26","author":"Howell","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The Role of Patient-Reported Outcome Measures in the Continuum of Cancer Clinical Care: ESMO Clinical Practice Guideline\u2606","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.annonc.2021.12.010","article-title":"The Use of Patient-Reported Outcomes (PROs) in Cancer Care: A Realistic Strategy","volume":"33","author":"Minvielle","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_31","first-page":"61","article-title":"Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv. Insights"},{"key":"ref_32","first-page":"1015","article-title":"Patient-reported Outcome Measures (PROMs): A Review of Generic and Condition-specific Measures and a Discussion of Trends and Issues","volume":"24","author":"Churruca","year":"2021","journal-title":"Health Expect. Int. J. Public Particip. Health Care Health Policy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1111\/j.1524-4733.2007.00272.x","article-title":"What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?","volume":"10","author":"Frost","year":"2007","journal-title":"Value Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e057950","DOI":"10.1136\/bmjopen-2021-057950","article-title":"Evaluation of the Psychometric Properties of Patient-Reported and Clinician-Reported Outcome Measures of Chemotherapy-Induced Peripheral Neuropathy: A COSMIN Systematic Review Protocol","volume":"12","author":"Tapp","year":"2022","journal-title":"BMJ Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1188\/16.CJON.20-01AP","article-title":"Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature","volume":"20","author":"Curcio","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Psychometric Properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1188\/17.ONF.E111-E123","article-title":"Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review","volume":"44","author":"Haryani","year":"2017","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1007\/s11136-022-03154-7","article-title":"Assessing Chemotherapy-Induced Peripheral Neuropathy with Patient Reported Outcome Measures: A Systematic Review of Measurement Properties and Considerations for Future Use","volume":"31","author":"Li","year":"2022","journal-title":"Qual. Life Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1111\/jns.12333","article-title":"Overview and Critical Revision of Clinical Assessment Tools in Chemotherapy-Induced Peripheral Neurotoxicity","volume":"24","author":"Park","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-Assessed and Patient-Reported Outcome Measures in Chemotherapy-Induced Sensory Peripheral Neurotoxicity: Two Sides of the Same Coin","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN Guideline for Systematic Reviews of Patient-Reported Outcome Measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Justesen, T., Freyberg, J., and Schultz, A.N.\u00d8. (2021). Database Selection and Data Gathering Methods in Systematic Reviews of Qualitative Research Regarding Diabetes Mellitus\u2014An Explorative Study. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01281-2"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal Database Combinations for Literature Searches in Systematic Reviews: A Prospective Exploratory Study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.07-9492LSF","article-title":"Comparison of PubMed, Scopus, Web of Science, and Google Scholar: Strengths and Weaknesses","volume":"22","author":"Falagas","year":"2008","journal-title":"FASEB J."},{"key":"ref_46","unstructured":"Patient-Reported Outcome Measurement Group (2024, April 04). Prom Group Construct & Instrument Type Filters February 2010. Available online: https:\/\/cosmin.nl\/wp-content\/uploads\/prom-search-filter-oxford-2010.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11136-009-9528-5","article-title":"Development of a Methodological PubMed Search Filter for Finding Studies on Measurement Properties of Measurement Instruments","volume":"18","author":"Terwee","year":"2009","journal-title":"Qual. Life Res."},{"key":"ref_48","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Pagel, J.M., and Welch, V. (2023). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4, The Cochrane Collaboration."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","article-title":"COSMIN Risk of Bias Checklist for Systematic Reviews of Patient-Reported Outcome Measures","volume":"27","author":"Mokkink","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","article-title":"COSMIN Methodology for Evaluating the Content Validity of Patient-Reported Outcome Measures: A Delphi Study","volume":"27","author":"Terwee","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_51","unstructured":"Terwee, C.B., Prinsen, C.A., de Vet, H.C.W., Bouter, L.M., Alonso, J., Westerman, M.J., Patrick, D.L., and Mokkink, L.B. (2018). COSMIN Methodology for Assessing the Content Validity of PROMs, VU University Medical Center."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality Criteria Were Proposed for Measurement Properties of Health Status Questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11136-011-9960-1","article-title":"Rating the Methodological Quality in Systematic Reviews of Studies on Measurement Properties: A Scoring System for the COSMIN Checklist","volume":"21","author":"Terwee","year":"2012","journal-title":"Qual. Life Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13643-022-01994-5","article-title":"Study Protocol for Developing, Piloting and Disseminating the PRISMA-COSMIN Guideline: A New Reporting Guideline for Systematic Reviews of Outcome Measurement Instruments","volume":"11","author":"Elsman","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4143\/crt.2017.361","article-title":"Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jpainsymman.2008.05.013","article-title":"Development of a Novel Location-Based Assessment of Sensory Symptoms in Cancer Patients: Preliminary Reliability and Validity Assessment","volume":"37","author":"Burkey","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2021.08.022","article-title":"Development and Validation of the Measure of Ovarian Symptoms and Treatment Concerns for Surveillance (MOST-S26): An Instrument to Complement the Clinical Follow-up of Women with Ovarian Cancer after Completion of First-Line Treatment","volume":"163","author":"Campbell","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s41687-021-00377-z","article-title":"Measurement Properties of Brief Neuropathy Screening Items in Cancer Patients Receiving Taxanes, Platinums, or Proteasome Inhibitors","volume":"5","author":"Knoerl","year":"2021","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11136-013-0470-1","article-title":"Cognitive Interviewing of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"23","author":"Hay","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s00520-017-3764-y","article-title":"Electronic versus Paper-Pencil Methods for Assessing Chemotherapy-Induced Peripheral Neuropathy","volume":"25","author":"Knoerl","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"RTNP-2022-0037.R1","DOI":"10.1891\/RTNP-2022-0037","article-title":"Psychometric Properties of the Korean Version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool","volume":"36","author":"Jung","year":"2022","journal-title":"Res. Theory Nurs. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejon.2017.10.001","article-title":"The Psychometric Properties of the Turkish Version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT)","volume":"31","author":"Kahraman","year":"2017","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pmn.2020.05.005","article-title":"Validation of the Arabic Version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool","volume":"21","author":"Obaid","year":"2020","journal-title":"Pain Manag. Nurs."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4103\/apjon.apjon_29_18","article-title":"Reliability and Validity of the Turkish Version of Chemotherapy-Induced Peripheral Neuropathy Assessment Tool for Breast Cancer Patients Receiving Taxane Chemotherapy","volume":"5","author":"Simsek","year":"2018","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1097\/NCC.0b013e31820251de","article-title":"Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool","volume":"34","author":"Tofthagen","year":"2011","journal-title":"Cancer Nurs."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The Development of an EORTC Quality of Life Questionnaire to Assess Chemotherapy-Induced Peripheral Neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing Patient-Reported Peripheral Neuropathy: The Reliability and Validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Barton","year":"2013","journal-title":"Qual. Life Res."},{"key":"ref_70","first-page":"1","article-title":"Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients","volume":"2","author":"Liu","year":"2015","journal-title":"SOJ Anesth. Pain Manag."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s11136-017-1626-1","article-title":"Evaluation of the Psychometric Properties of the EORTC Chemotherapy-Induced Peripheral Neuropathy Questionnaire (QLQ-CIPN20)","volume":"26","author":"Kieffer","year":"2017","journal-title":"Qual. Life Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure","volume":"44","author":"Haupt","year":"2017","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1073274818756608","DOI":"10.1177\/1073274818756608","article-title":"In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials","volume":"25","author":"Smith","year":"2018","journal-title":"Cancer Control"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00520-018-4553-y","article-title":"Rasch Model-Based Testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) Using Alliance for Clinical Trials in Oncology (Alliance) A151408 Study Data","volume":"27","author":"Zanville","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/NCC.0000000000000596","article-title":"Psychometric Testing of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PeriNomS) and Alliance for Clinical Trials in Oncology (Alliance) A151408 Study Data","volume":"42","author":"Banerjee","year":"2019","journal-title":"Cancer Nurs."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization Study: From Consensus to the First Validity and Reliability Findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/23279095.2019.1677232","article-title":"Psychometric Evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20)","volume":"28","year":"2021","journal-title":"Appl. Neuropsychol. Adult"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4040\/jkan.2014.44.6.735","article-title":"Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-Induced Peripheral Neuropathy","volume":"44","author":"Kim","year":"2014","journal-title":"J. Korean Acad. Nurs."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1007\/s00520-019-04771-8","article-title":"Minimal Clinically Important Difference of the EORTC QLQ-CIPN20 for Worsening Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy","volume":"27","author":"Yeo","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_80","first-page":"741","article-title":"Psychometric Evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) Questionnaire for Patients Receiving Systemic Chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","article-title":"Psychometric Testing of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT\/GOG-Ntx) Subscale in a Longitudinal Study of Cancer Patients Treated with Chemotherapy","volume":"18","author":"Cheng","year":"2020","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4251\/wjgo.v12.i2.205","article-title":"Neuropathy Experienced by Colorectal Cancer Patients Receiving Oxaliplatin: A Qualitative Study to Validate the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity Scale","volume":"12","author":"Kaiser","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6533797","DOI":"10.1155\/2022\/6533797","article-title":"Validation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population","volume":"2022","author":"Ribeiro","year":"2022","journal-title":"Int. J. Breast Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ajco.13000","article-title":"Longitudinal Validation and Comparison of the Chinese Version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity Subscale (FACT\/GOG-Ntx)","volume":"15","author":"Cheng","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and Reduction of FACT\/GOG-Ntx Subscale for Platinum\/Paclitaxel-Induced Neurologic Symptoms: A Gynecologic Oncology Group Study","volume":"17","author":"Huang","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the Side Effects of Taxane Therapy in Oncology: The Functional Assesment of Cancer Therapy-Taxane (FACT-Taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","article-title":"Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity","volume":"97","author":"Alberti","year":"2021","journal-title":"Neurology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and Validity of the Patient Neurotoxicity Questionnaire during Taxane Chemotherapy in a Phase III Randomized Trial in Patients with Breast Cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support. Care Cancer"},{"key":"ref_89","first-page":"e14324","article-title":"Validation of the Patient Neurotoxicity Questionnaire for Patients Suffering from Chemotherapy-Induced Peripheral Neuropathy in Greek","volume":"13","author":"Tsoleridis","year":"2021","journal-title":"Cureus"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jpain.2015.07.002","article-title":"Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale","volume":"16","author":"Mendoza","year":"2015","journal-title":"J. Pain"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41687-020-0180-8","article-title":"The Treatment-induced Neuropathy Assessment Scale (TNAS): A psychometric update following qualitative enrichment","volume":"4","author":"Mendoza","year":"2020","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00520-015-2838-y","article-title":"Reliability Testing of Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ), a Pilot Study","volume":"24","author":"Gustafsson","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Leonard, G.D., Wright, M.A., Quinn, M.G., Fioravanti, S., Harold, N., Schuler, B., Thomas, R.R., and Grem, J.L. (2005). Survey of Oxaliplatin-Associated Neurotoxicity Using an Interview-Based Questionnaire in Patients with Metastatic Colorectal Cancer. BMC Cancer, 5.","DOI":"10.1186\/1471-2407-5-116"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","article-title":"Chemotherapy-Induced Neuropathy in Multiple Myeloma: Influence on Quality of Life and Development of a Questionnaire to Compose Common Toxicity Criteria Grading for Use in Daily Clinical Practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.ejca.2013.04.004","article-title":"Rasch-Built Overall Disability Scale for Patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN-R-ODS)","volume":"49","author":"Binda","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gu, Z., Chen, C., Gu, J., Song, Z., Wei, G., Cai, G., Shu, Q., Zhu, L., Zhu, W., and Deng, H. (2023). Development and Validation of the Chemotherapy-Induced Peripheral Neuropathy Integrated Assessment\u2014Oxaliplatin Subscale: A Prospective Cohort Study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11541-7"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kanda, K., Fujimoto, K., Mochizuki, R., Ishida, K., and Lee, B. (2019). Development and Validation of the Comprehensive Assessment Scale for Chemotherapy-Induced Peripheral Neuropathy in Survivors of Cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6113-3"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00520-018-4391-y","article-title":"Concept Domain Validation and Item Generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS)","volume":"27","author":"Williams","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2169\/internalmedicine.54.3318","article-title":"Validity of the chemotherapy-induced peripheral neuropathy self-check sheet","volume":"54","author":"Miyoshi","year":"2015","journal-title":"Intern Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"104588","DOI":"10.1016\/j.ijnurstu.2023.104588","article-title":"The Effectiveness of Symptom Management Interventions Based on Electronic Patient-Reported Outcomes (ePROs) for Symptom Burden, Quality of Life, and Overall Survival among Patients with Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"147","author":"Li","year":"2023","journal-title":"Int. J. Nurs. Stud."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"151354","DOI":"10.1016\/j.soncn.2022.151354","article-title":"A Systematic Review of Systematic Reviews and Pooled Meta-Analysis on Psychosocial Interventions for Improving Cancer-Related Fatigue","volume":"39","author":"Belloni","year":"2023","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1097\/NNR.0000000000000605","article-title":"A Concept Development for the Symptom Science Model 2.0","volume":"71","author":"Graves","year":"2022","journal-title":"Nurs. Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Boateng, G.O., Neilands, T.B., Frongillo, E.A., Melgar-Qui\u00f1onez, H.R., and Young, S.L. (2018). Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. Front. Public Health, 6.","DOI":"10.3389\/fpubh.2018.00149"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1049732318783186","article-title":"Qualitative Methods Used to Generate Questionnaire Items: A Systematic Review","volume":"29","author":"Ricci","year":"2019","journal-title":"Qual. Health Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.4103\/sja.SJA_203_17","article-title":"Guidelines for Developing, Translating, and Validating a Questionnaire in Perioperative and Pain Medicine","volume":"11","author":"Tsang","year":"2017","journal-title":"Saudi J. Anaesth."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:48:14Z","timestamp":1760114894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":105,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["curroncol31120577"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31120577","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}